今年以来,时而出现一些发起式基金在净值上升的过程中清盘,甚至包括重仓势头正好的医药板块基金。与市场“挥手作别”的主要原因系这些发起式基金在成立三年后,在规模大考面前闯关失败。以华安创新医药锐选量化为例,截至去年末,该基金前十大重仓股中包括了恒瑞医药、泽璟制药、药明生物、百济神州等年内涨幅可观的个股。因此,截至4月1日,该基金年内净值涨幅高达22%,然而上涨势头却在一季度末戛然而止。作为一只发起式...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.